Peter Schmid MD PhD; ASCO 2026: Giredestrant Beats Standard Endocrine Therapies Irrespective of Menopausal Status in Patients with ER+, HER2- Early Breast Cancer episode artwork

EPISODE · Jun 5, 2026 · 8 MIN

Peter Schmid MD PhD; ASCO 2026: Giredestrant Beats Standard Endocrine Therapies Irrespective of Menopausal Status in Patients with ER+, HER2- Early Breast Cancer

from Audio Journal of Oncology Podcast

Giredestrant Beats Standard Endocrine Therapies Irrespective of Menopausal Status in Patients with ER+, HER2- Early Breast Cancer An interview with: Peter Schmid MD PhD, Professor of Cancer Medicine;

Episode metadata supplied by the publisher feed · Published Jun 5, 2026

Embed this episode

NOW PLAYING

Peter Schmid MD PhD; ASCO 2026: Giredestrant Beats Standard Endocrine Therapies Irrespective of Menopausal Status in Patients with ER+, HER2- Early Breast Cancer

0:00 8:30

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Audio Journal of Oncology Podcast?

This episode is 8 minutes long.

When was this Audio Journal of Oncology Podcast episode published?

This episode was published on June 5, 2026.

Can I download this Audio Journal of Oncology Podcast episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!